BOSTON and GLASGOW, September 12, 2023 – Dewpoint Therapeutics and Chemify today announced a partnership to develop a suite of digitally […]

A powerful collaboration between researchers from the Max Planck Institute, Agnes Toth-Petroczy and Dewpoint co-founder Anthony Hyman, and the Dewpoint […]

Boston, Massachusetts March 22, 2023 – Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates […]

BOSTON, Nov. 14, 2022 — Dewpoint Therapeutics Inc. today announced the U.S. Patent and Trademark Office (USPTO) issued the patent “Methods of Characterizing […]

BOSTON, Massachusetts, August 17, 2022 – A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates […]

BOSTON, September 22, 2022 – Dewpoint Therapeutics, Inc. today announced biomolecular scientist Anthony (Tony) Hyman, a co-founder of Dewpoint Therapeutics and Director […]

A new perspective on the principles and functions of condensate modifying drugs (c-mods) was published in Frontiers in Molecular Biosciences.

BOSTON, May 25, 2022 — Dewpoint Therapeutics Inc., today announced the US Patent and Trademark Office (USPTO) issued the patent “Methods of […]

BOSTON , February 3, 2022 – Dewpoint Therapeutics Inc., the biomolecular condensates company, today announced the completion of a $150 million Series C financing.

Isaac Klein, M.D., Ph.D. How did the discovery of condensates transform our understanding of the cell? We thought the cell […]